Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 8, 2025

Brilliant Violet 785(TM) anti-mouse CD223 (LAG-3)

RRID:AB_2566571
Type: Antibody

Proper Citation

(BioLegend Cat# 125219, RRID:AB_2566571)

Antibody Information

URL: http://antibodyregistry.org/AB_2566571

Proper Citation: (BioLegend Cat# 125219, RRID:AB_2566571)

Target Antigen: CD223

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD223 (LAG-3)

Description: This monoclonal targets CD223

Target Organism: mouse

Clone ID: Clone C9B7W

Antibody ID: AB_2566571

Vendor: BioLegend

Catalog Number: 125219

Record Creation Time: 20231110T035152+0000

Record Last Update: 20240725T011341+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD223 (LAG-3).

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD223 (LAG-3).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Guo HZ, et al. (2024) A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. Cell reports. Medicine, 5(6), 101592.

Andreata F, et al. (2024) Therapeutic potential of co-signaling receptor modulation in hepatitis B. Cell, 187(15), 4078.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. Immunity, 57(2), 287.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med (New York, N.Y.), 4(5), 326.

Kilian M, et al. (2023) MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer cell, 41(2), 235.

Guo H, et al. (2023) DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs. Cell, 186(13), 2765.

Zander R, et al. (2022) Delineating the transcriptional landscape and clonal diversity of virus-specific CD4+ T cells during chronic viral infection. eLife, 11.

Uzhachenko RV, et al. (2021) Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell reports, 35(1), 108944.

Burger ML, et al. (2021) Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell, 184(19), 4996.

Srivastava S, et al. (2021) Immunogenic Chemotherapy Enhances Recruitment of CAR-T

Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer cell, 39(2), 193.

Kumagai S, et al. (2020) An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. Immunity, 53(1), 187.

Benci JL, et al. (2019) Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell, 178(4), 933.

Benci JL, et al. (2016) Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 167(6), 1540.